Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0781
    -0.0013 (-0.12%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2624
    +0.0002 (+0.01%)
     
  • USD/JPY

    151.3740
    +0.0020 (+0.00%)
     
  • Bitcoin USD

    70,297.67
    -15.04 (-0.02%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Reminds Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / August 31, 2016 / Khang & Khang LLP (the "Firm") announces a class action lawsuit has been filed against Emergent BioSolutions, Inc. ("Emergent" or the "Company") (EBS). Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 inclusive (the "Class Period"), are encouraged to contact the Firm prior to the September 19, 2016 lead plaintiff motion deadline.

If you purchased Emergent shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, Emergent issued materially false and misleading statements about its business and financial prospects, specifically relating to future lucrative contract renewals and demand from the U.S. government for its anthrax vaccine BioThrax. These statements caused the Company's common stock to trade at artificially inflated prices, which certain defendants sold. On June 22, 2016, Emergent announced that the U.S. government issued notices that it would be purchasing fewer doses than investors were led to believe, and that when newer and faster next-generation antrax vaccines are developed and approved, the Company would lose its procurement contract exclusivity. When this news was released to the public, shares of the stock decreased in value, causing investors harm.

If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

Advertisement